Eli Lilly LLY Leader in obesity and diabetes drugs (Zepbound, Mounjaro), strong pipeline, exceptional earnings growth
Global Markets | Healthcare Equity Research Eli Lilly (NYSE: LLY): The Undisputed Leader in Obesity & Diabetes Care Zepbound, Mounjaro and a Deepening Pipeline Keep the Growth Story Intact By WealthChartX Desk | July 23, 2026 | Sector: Pharmaceuticals & Biotechnology Eli Lilly and Company (NYSE: LLY) has cemented its position as the world's most valuable pharmaceutical franchise, riding an unprecedented wave of demand for its GLP-1 based obesity and diabetes therapies. With a market capitalization that has now crossed $1.10 trillion , Lilly's combination of blockbuster drug sales, expanding margins and a deep late-stage pipeline continues to draw both institutional and retail investor attention globally — including growing interest from Indian investors accessing US markets via the RBI's Liberalised Remittance Scheme (LRS). Stock Snapshot Metric Value ...